ARCT-154 (English Wikipedia)

Analysis of information sources in references of the Wikipedia article "ARCT-154" in English language version.

refsWebsite

Global rank English rank

3vnexpress.net

839^th place

2,307^th place

2yahoo.com

38^th place

40^th place

2businesswire.com

615^th place

407^th place

1wipo.int

1,462^nd place

1,223^rd place

1bloomberg.com

99^th place

77^th place

1csl.com

low place

1biopharma-reporter.com

low place

1reuters.com

49^th place

47^th place

1tuoitre.vn

1,481^st place

7,695^th place

1thanhnien.vn

2,191^st place

9,371^st place

1fool.com

4,183^rd place

2,600^th place

1laodong.vn

5,345^th place

low place

1baochinhphu.vn

6,451^st place

low place

1doi.org

2^nd place

1nih.gov

4^th place

baochinhphu.vn

"Kết quả bước đầu của vaccine ARCT-154". Vietnam Government Portal. 29 September 2021.

biopharma-reporter.com

Arthur R (2 August 2021). "Arcturus Therapeutics lines up Phase 1/2/3 trial for next-generation mRNA COVID-19 vaccine". Biopharma Reporter.

bloomberg.com

Giang NK (2 August 2021). "Arcturus Allows Vietnam's Vingroup to Make Covid Vaccines". Bloomberg.

businesswire.com

csl.com

newsroom.csl.com

"Japan's Ministry of Health, Labour and Welfare Approves CSL and Arcturus Therapeutics' ARCT-154, the first Self-Amplifying mRNA vaccine approved for COVID in adults". CSL. Retrieved 12 July 2024.

doi.org

Oda Y, Kumagai Y, Kanai M, Iwama Y, Okura I, Minamida T, et al. (April 2024). "Immunogenicity and safety of a booster dose of a self-amplifying RNA COVID-19 vaccine (ARCT-154) versus BNT162b2 mRNA COVID-19 vaccine: a double-blind, multicentre, randomised, controlled, phase 3, non-inferiority trial". The Lancet. Infectious Diseases. 24 (4): 351–360. doi:10.1016/S1473-3099(23)00650-3. PMID 38141632.

fool.com

"Why Arcturus Therapeutics Stock Is Soaring Today". The Motley Fool. 3 August 2021.

laodong.vn

Lin T (2 August 2021). "Cho phép thử nghiệm lâm sàng vaccine COVID-19 mua công nghệ mRNA của Mỹ" [American mRNA Covid-19 vaccine candidate gets green light for trial]. Lao Động (in Vietnamese).

nih.gov

pubmed.ncbi.nlm.nih.gov

Oda Y, Kumagai Y, Kanai M, Iwama Y, Okura I, Minamida T, et al. (April 2024). "Immunogenicity and safety of a booster dose of a self-amplifying RNA COVID-19 vaccine (ARCT-154) versus BNT162b2 mRNA COVID-19 vaccine: a double-blind, multicentre, randomised, controlled, phase 3, non-inferiority trial". The Lancet. Infectious Diseases. 24 (4): 351–360. doi:10.1016/S1473-3099(23)00650-3. PMID 38141632.

reuters.com

"Arcturus to start clinical trial of COVID-19 vaccine in Vietnam". Reuters. 2 August 2021.

thanhnien.vn

Châu L (2 August 2021). "Vingroup tiếp nhận công nghệ sản xuất vắc xin Covid-19 chống lại các biến chủng mới" [Vingroup receives Covid-19 vaccine technology transfer to fight against new variants]. Thanh Niên (in Vietnamese).

tuoitre.vn

Huynh M (2 August 2021). "Vingroup nhận chuyển giao độc quyền công nghệ sản xuất vắc xin mRNA phòng COVID-19" [Vingroup receives exclusive technology transfer for COVID-19 mRNA vaccines]. Tuổi Trẻ (in Vietnamese).

vnexpress.net

"Sắp thử nghiệm vaccine Covid-19 thứ ba của Việt Nam" [Vietnam set to start third Covid-19 vaccine trial]. VnExpress (in Vietnamese). 2 August 2021.
"100 người đầu tiên sắp tiêm thử vaccine Covid thứ ba của Việt Nam". VnExpress (in Vietnamese). 14 August 2021.
"Thử nghiệm vaccine ARCT-154 giai đoạn 2 và 3a" (in Vietnamese). VnExpress. 29 September 2021. Retrieved 29 September 2021.

wipo.int

"Patent Landscape Report COVID-19-related vaccines and therapeutics" (PDF).

ARCT-154 (English Wikipedia)

baochinhphu.vn

biopharma-reporter.com

bloomberg.com

businesswire.com

csl.com

newsroom.csl.com

doi.org

fool.com

laodong.vn

nih.gov

pubmed.ncbi.nlm.nih.gov

reuters.com

thanhnien.vn

tuoitre.vn

vnexpress.net

wipo.int

yahoo.com

finance.yahoo.com